1-(4-methylbenzyl)-1H-1,2,4-triazole | 143131-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-methylbenzyl)-1H-1,2,4-triazole
• 英文别名: 1-[(4-methylphenyl)methyl]-1,2,4-triazole
• CAS: 143131-65-1
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: ONPUEMGBKGCDOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-methylbenzyl)-1H-1,2,4-triazole 、 乙醛 以The product was isolated as a white solid in 86% yield的产率得到1-[1-(4-methylbenzyl)-1H-1,2,4-triazol-5-yl]ethanol
  参考文献：
  名称：

  Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole

  摘要：

  提供了降低β淀粉样蛋白水平的化合物。该化合物具有公式Ia的结构：其中，R1是较低的烷基，取代的较低的烷基，苯基，取代的苯基，苄基，取代的苄基，苄氧基，取代的苄氧基或SO2R5；R5是苯基，取代的苯基，杂环，取代的杂环，烷基或取代的烷基；R2是较低的烷基，取代的较低的烷基，CF3，烯基，取代的烯基，炔基，取代的炔基，苯基，取代的苯基或环烷基；R3是氢，较低的烷基或取代的较低的烷基；R4是苯基，取代的苯基，杂环，取代的杂环，噻吩或取代的噻吩；R6是氢，较低的烷基，取代的较低的烷基，CF3，烯基，取代的烯基，炔基，取代的炔基，苯基，取代的苯基，环烷基或取代的环烷基；W、X和Y分别是CR7或N；R7是氢，卤素，较低的烷基或取代的较低的烷基。

  公开号：

  US20100144812A1
• 作为产物：
  描述：

  1H-1,2,4-三唑 、 4-甲基苄溴 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4-methylbenzyl)-1H-1,2,4-triazole
  参考文献：
  名称：

  新型杂环磺酰胺γ-分泌酶抑制剂的合成及其构效关系

  摘要：

  业已证明，γ-分泌酶抑制剂可减少β-淀粉样蛋白的产生，β-淀粉样蛋白是在阿尔茨海默氏病患者的大脑中发现的斑块的一种成分。据报道，一系列新的杂环磺酰胺γ-分泌酶抑制剂可降低细胞中的β-淀粉样蛋白水平。与Notch（一种替代的γ-分泌酶底物）相比，该系列化合物的几个实例显示出更高的抑制淀粉样蛋白前体蛋白加工的倾向。

  DOI：

  10.1016/j.bmc.2009.04.052

文献信息

• ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
  申请人：Johnson Neil W.

  公开号：US20080182852A1

  公开（公告）日：2008-07-31

  The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

  本发明涉及以下公式所代表的化合物： 或其药学上可接受的盐； 其中R1、R2、R3、R4、r和s如前所定义。本发明的化合物在治疗与Aurora激酶活性相关的疾病，如癌症方面是有用的。
• NOVEL PROCESS
  申请人：Gore Vinayak G.

  公开号：US20100256208A1

  公开（公告）日：2010-10-07

  The present invention relates to a novel process for the preparation of rizatriptan and its pharmaceutically acceptable salts. It provides a novel process for the preparation of highly pure rizatriptan, which can be easily adopted for commercial production with a high degree of consistency in purity and yield. Subsequently the rizatriptan base prepared can be converted into any suitable pharmaceutically acceptable salt, such as the oxalate, succinate or benzoate salt, for dosage form preparation. The present invention also provides a composition comprising rizatriptan useful for the manufacture of a medicament for the treatment or prevention of migraine.

  本发明涉及一种制备瑞佐托品及其药用可接受盐类的新工艺。它提供了一种制备高纯度瑞佐托品的工艺，该工艺可以轻松地用于商业生产，且在纯度和收率方面具有高度一致性。随后，所制备的瑞佐托品碱可以转化为任何合适的药用可接受盐，例如草酸盐、琥珀酸盐或苯甲酸盐，用于制备剂型。本发明还提供了一种包含瑞佐托品的组合物，该组合物用于制造用于治疗或预防偏头痛的药物。
• [EN] 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS<br/>[FR] DÉRIVÉS DE 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE ET COMPOSÉS ASSOCIÉS QUI SE FIXENT AU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE (S1P) DANS LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
  申请人：SERONO LAB

  公开号：WO2009019167A1

  公开（公告）日：2009-02-12

  The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

  这项发明涉及式(I)的化合物：其中X、W、Q、R、R1和R2的含义如权利要求1所述。该化合物在治疗自身免疫性疾病（如多发性硬化症）方面是有用的。
• Non-basic melanin concentrating hormone receptor-1 antagonists
  申请人：Ahmad Saleem

  公开号：US20070093508A1

  公开（公告）日：2007-04-26

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外，本申请提供了含有至少一种根据式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱（例如肥胖症、糖尿病、抑郁症或焦虑症）的患者的方法，通过给予根据式I的化合物的治疗有效剂量。
• Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole
  申请人：Resnick Lynn

  公开号：US20050171180A1

  公开（公告）日：2005-08-04

  Compounds useful for lowering beta amyloid levels are provided. The compounds have the structure of formula Ia: wherein, R 1 is lower alkyl, substituted lower alkyl, phenyl, substituted phenyl, benzyl, substituted benzyl, benzyloxy, substituted benzyloxy, or SO 2 R 5 ; R 5 is phenyl, substituted phenyl, heterocycle, substituted heterocycle, alkyl, or substituted alkyl; R 2 is lower alkyl, substituted lower alkyl, CF 3 , alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, or cycloalkyl; R 3 is hydrogen, lower alkyl, or substituted lower alkyl; R 4 is phenyl, substituted phenyl, heterocycle, substituted heterocycle, thiophene, or substituted thiophene; R 6 is hydrogen, lower alkyl, substituted lower alkyl, CF 3 , alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, cycloalkyl, or substituted cycloalkyl; W, X and Y are independently CR 7 or N; and R 7 is hydrogen, halogen, lower alkyl, or substituted lower alkyl.

  提供了降低β淀粉样蛋白水平的化合物。这些化合物具有如下式Ia的结构：其中，R1是较低的烷基，取代的较低烷基，苯基，取代的苯基，苄基，取代的苄基，苄氧基，取代的苄氧基，或SO2R5；R5是苯基，取代的苯基，杂环，取代的杂环，烷基，或取代的烷基；R2是较低的烷基，取代的较低烷基，CF3，烯基，取代的烯基，炔基，取代的炔基，苯基，取代的苯基，或环烷基；R3是氢，较低的烷基，或取代的较低烷基；R4是苯基，取代的苯基，杂环，取代的杂环，噻吩，或取代的噻吩；R6是氢，较低的烷基，取代的较低烷基， ，烯基，取代的烯基，炔基，取代的炔基，苯基，取代的苯基，环烷基，或取代的环烷基；W、X和Y独立地是CR7或N；而R7是氢，卤素，较低的烷基，或取代的较低烷基。